Managing diabetes in pregnancy requires a dual approach: lifestyle changes like diet and exercise, plus targeted drug therapy with insulin or antihyperglycemics. Early action, patient education, and tools like CGM and telemedicine enhance glycemic control and outcomes.
Use of intravenous lipid emulsions in drug-induced toxicities: a 2025 narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41247632/
Intravenous lipid emulsions (ILE) were first proposed in 1998 as a treatment for bupivacaine-induced cardiac arrest. Since then, their use has expanded to include poisonings by various lipophilic drugs such...
ILEs treat lipophilic drug toxicities through lipid sink, shuttle, and cardiotonic mechanisms; benefits shown in select poisonings, but mortality impact, optimal dosing, and indications remain uncertain, requiring higher-quality evidence.
Evaluating the impact of testosterone replacement therapy on carotid atherosclerosis: a systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39183456/
Aim: This meta-analysis investigates the association between testosterone replacement therapy [TRT] and carotid artery atherosclerosis. Methods: 3 databases were searched for studies up to June 2023 per the PRISMA guidelines....
Testosterone therapy shows no association with carotid atherosclerosis or lipid/inflammatory markers, though it raises testosterone levels, suggesting safe use in hypogonadal men without increasing CIMT risk.

Patient Background: A 79-year-old woman presented with persistent hypophosphatemia (serum phosphorus 0.8 mg/dL) and multiple stress fractures involving the ribs, spine, and pelvis, consistent with osteomalacia. Her medical history included type 2 diabetes mellitus, hypertension, obesity, osteoarthritis, and anxiety disorder.
Assessment and Diagnosis: Initial evaluation revealed severe hypophosphatemia (0.8 mg/dL; NR: 2.5–4.5 mg/dL), elevated parathyroid hormone (PTH, 169 pg/mL; NR: 10–65 pg/mL), and normal serum calcium levels. Despite vitamin D supplementation, hypophosphatemia persisted (1.7 mg/dL in 2023), and hypercalcemia developed later (10.9 mg/dL; NR: 8.5–10.2 mg/dL). Renal studies showed phosphate wasting (tubular reabsorption of phosphate [TRP] 56.2%) and elevated fibroblast growth factor 23 (FGF-23, 1694 kRU/L). In 2024, ^18F-fluorocholine PET-CT imaging identified two right parathyroid adenomas, confirming a diagnosis of primary hyperparathyroidism (PHPT).
- How can chronic hypophosphatemia signal early-stage PHPT?
- Why is postoperative monitoring vital in PHPT care?


